MinervaX is a biotechnology company focused on developing vaccines for infectious diseases. The company's lead candidate is a vaccine designed to prevent Group B Streptococcus (GBS) infections, which are a major cause of neonatal and maternal infections.

Minervax ApS

MinervaX

MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.

Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns.  Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery.  Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability.

Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.


MinervaX is highlighted as one of six top companies at the forefront of the antibiotic resistance field 😀 

https://lnkd.in/dNicpRJN


Proud to share the news that MinervaX won Entrepreneur of the Year 2023 in the Life Science Category last night.

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus 


Listen today to Chief Executive Officer, @Per Fischer as he discusses the Global Burden of Group B Streptococcus and @Minervax ApS's focus as it aims to address the issue with its novel, prophylactic GBS vaccine with Editor in Chief @Jim Cornall on @labiotech.eu's weekly 'Beyond Biotech' podcast.

Full podcast available below

#MinervaX has developed a novel, clinical #GBS pipeline which has the potential to reduce deaths associated with GBS across the population as it continues to tackle the urgent unmet medical need, worldwide. 

Learn more about MinervaX on www.minervax.com and its ongoing clinical trials.

#Biotech #maternalvaccine #adjuventedproteinsantigens #neonatalinvasivedisease #GroupBStreptococcus

COM:MINERVAX

MinervaX

locale

market

industry

website

crunchbase

linkedin

investor of

competitor of

Metrics